References
- Walan A, Bader J-P, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320: 69–75
- McFarland RJ, Bateson C, Green JRB, et al. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology 1990; 98: 278–83
- Maton PN. Omeprazole. N Engl J Med 1991; 324: 965–75
- Jeffreys DB, Vale JA. Cimetidine and bradycardia. Lancet 1978; 2: 828
- Johnson WS, Miller DR. Ranitidine and bradycardia. Ann Intern Med 1988; 108: 493–6
- Tordjman T, Korzets A, Kotas R, Manor J, Klajman A. Complete atrioventricular block and long-term cimetidine therapy. Arch Intern Med 1984; 144: 861–3
- Nicolic G, Singh JB. Cimetidine, vasopressin and chronotropic incompetence. Med J Aust 1982; 2: 435–6
- Hinrichsen H, Halabi A, Kirch W. Haemodynamic effects of H2-receptor antagonists. Eur J Clin Invest 1992; 22: 9–18
- Black JW, Duncan WAM, Durant CJ, Ganelin CR, Parsons EM. Definition and antagonism of histamine H2-receptors. Nature 1972; 236: 385–90
- Kirch W, Halabi A, Linde M, Santos SR, Ohnhaus EE. Negative effects of famotidine on cardiac performance assessed by noninvasive hemodynamic measurements. Gastroenterology 1989; 96: 1388–92
- Hinrichsen H, Halabi A, Kirch W. Hemodynamic effects of different H2-receptor antagonists. Clin Pharmacol Ther 1990; 48: 302–8
- Halabi A, Kirch W. Negative chronotropic effects of nizatidine. Gut 1991; 32: 630–4
- Kirch W, Halabi A, Hinrichsen H. Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. Clin Pharmacol Ther 1992; 51: 325–33
- Dowie JL, Smith JE, MacGilchrist AJ. In vivo and in vitro studies of the site of inhibitory action of omeprazole on adrenocortical steroidogenesis. Eur J Clin Pharmacol 1988; 35: 625–9
- Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89: 1235–41
- Halabi A, Nokhodian A, Kirch W. Hemodynamic effects of roxatidine, an H2-receptor antagonist. Clin Invest 1992; 70: 118–21
- Kubicek WG, Karnegis JN, Patterson RP, Witsoe DA, Mattson RM. Development and evaluation of an impedance cardiac output system. Aerospace Med 1966; 37: 1208–12
- Sachs L. Applied statistics. 2nd ed. Springer, Berlin 1984; 395–403; 293–303
- Weissler AM, Harris WS, Schoenfeld CD. Systolic time intervals in heart failure in man. Circulation 1968; 37: 149–56
- Spodick D, Doi YL, Bishop RL, Hashimoto T. Systolic time intervals reconsidered. Reevaluation of the preejection period. Absence of relation to heart rate. Am J Cardiol 1984; 53: 1667–70
- Linde M, Ohnhaus EE, Kirch W. Mechano- und impe-danzkardiographische Parameter bei Patienten mit Herz-insuffizienz unter Gabe eines Calcium-Antagonisten. Die Bedeutung des Heather-Index. Z Kardiol 1989; 78: 181–6
- Breithaupt K, Erb KA, Neumann B, Wolf GK, Belz GG. Comparison of four noninvasive techniques to measure stroke volume: dual beam doppler echoaortography, electrical impedance cardiography, mechanosphygmography and M mode echocardiography of the left ventricle. Am J Noninvas Cardiol 1990; 4: 203–9
- Edumunds AT, Godfrey S, Tooley M. Cardiac output measured by transthoracic impedance cardiography at rest, during exercise, and at various lung volumes. Clin Sci 1982; 63: 107–13
- Hetherington M, Teo KK, Haennel R, Greenwood P, Rossal RE, Kappagoda T. Use of impedance cardiography in evaluating the exercise response of patients with left ventricular dysfunction. Eur Heart J 1985; 6: 1016–24
- Eisenberg BM, Linss G, Gleich V, Romaniuk P, Zimmerman W, Stern L. Die Wertigkeit der Impedanzkardiographie im Vergleich zur Angiokardiographie. Z Klin Med 1985; 40: 657–9
- Bertaccini G, Coruzzi G, Poli E, Adami M. Pharmacology of the novel H2-antagonist famotidine: in vitro studies. Agents Actions 1986; 19: 180–7